STOCK TITAN

[SCHEDULE 13G/A] Spero Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Anson-managed entities reported beneficial ownership of 1,615,469 shares of Spero Therapeutics common stock, representing 2.9% of the 55,910,641 shares outstanding. The holdings are disclosed on a Schedule 13G/A dated for the event 06/30/2025 and signed on 08/14/2025 by representatives of Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo and Moez Kassam.

The filing states the shares are held by the Fund and that the position is held in the ordinary course of business and not to influence control of the issuer. Voting and dispositive power over the 1,615,469 shares is shown as shared (no sole power reported). The filing cites the issuer's outstanding share count from the issuer's May 13, 2025 quarterly report.

Entità gestite da Anson hanno dichiarato la proprietà beneficiaria di 1.615.469 azioni ordinarie di Spero Therapeutics, pari al 2,9% delle 55.910.641 azioni in circolazione. Le partecipazioni sono riportate in un Schedule 13G/A relativo all’evento del 30/06/2025 e firmato il 14/08/2025 da rappresentanti di Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo e Moez Kassam.

La comunicazione dichiara che le azioni sono detenute dal Fondo e che la posizione è mantenuta nell’ordinario svolgimento dell’attività e non per influenzare il controllo dell’emittente. Il potere di voto e dispositive sulle 1.615.469 azioni è indicato come condiviso (non è riportato alcun potere esclusivo). Il documento cita il conteggio delle azioni in circolazione dell’emittente tratto dal rapporto trimestrale dell’emittente del 13 maggio 2025.

Entidades gestionadas por Anson informaron la propiedad beneficiaria de 1.615.469 acciones ordinarias de Spero Therapeutics, lo que representa el 2,9% de las 55.910.641 acciones en circulación. Las tenencias se revelan en un Schedule 13G/A fechado para el evento 30/06/2025 y firmado el 14/08/2025 por representantes de Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo y Moez Kassam.

La presentación indica que las acciones están en poder del Fondo y que la posición se mantiene en el curso ordinario del negocio y no para influir en el control del emisor. El poder de voto y dispositvo sobre las 1.615.469 acciones figura como compartido (no se informa poder exclusivo). La presentación cita el número de acciones en circulación del emisor según el informe trimestral del emisor del 13 de mayo de 2025.

Anson이 관리하는 법인들은 Spero Therapeutics 보통주 1,615,469주에 대한 실소유자(beneficial ownership)를 신고했으며, 이는 발행주식 총수 55,910,641주의 2.9%에 해당합니다. 보유 내역은 2025-06-30 사건을 위한 Schedule 13G/A에 공개되어 있으며, Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo 및 Moez Kassam의 대리인이 2025-08-14에 서명했습니다.

서류에는 해당 주식이 펀드에 의해 보유되고 있으며 이 지분은 발행인의 지배력에 영향을 주기 위한 것이 아닌 통상적인 사업활동의 일환으로 보유된 것이라고 명시되어 있습니다. 1,615,469주에 대한 의결권 및 처분권은 공동으로 표시되어 있으며(단독 권한은 보고되지 않음) 문서는 발행인의 2025년 5월 13일 분기보고서에 기재된 발행주식 수를 인용하고 있습니다.

Des entités gérées par Anson ont déclaré la propriété bénéficiaire de 1 615 469 actions ordinaires de Spero Therapeutics, représentant 2,9% des 55 910 641 actions en circulation. Les avoirs sont divulgués dans un Schedule 13G/A daté pour l’événement du 30/06/2025 et signé le 14/08/2025 par des représentants d’Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo et Moez Kassam.

Le dépôt indique que les actions sont détenues par le Fonds et que la position est détenue dans le cadre normal des activités et non pour influencer le contrôle de l’émetteur. Le pouvoir de vote et le pouvoir discrétionnaire sur les 1 615 469 actions sont indiqués comme partagés (aucun pouvoir exclusif déclaré). Le dépôt cite le nombre d’actions en circulation de l’émetteur figurant dans le rapport trimestriel de l’émetteur du 13 mai 2025.

Von Anson verwaltete Einheiten meldeten die wirtschaftliche Eigentümerschaft an 1.615.469 Aktien der Stammaktien von Spero Therapeutics, was 2,9% der 55.910.641 ausstehenden Aktien entspricht. Die Bestände sind in einer Schedule 13G/A aufgeführt, datiert auf das Ereignis 30.06.2025 und am 14.08.2025 von Vertretern von Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo und Moez Kassam unterzeichnet.

Die Einreichung gibt an, dass die Aktien vom Fonds gehalten werden und die Position im normalen Geschäftsverlauf gehalten wird und nicht dazu dient, die Kontrolle über den Emittenten zu beeinflussen. Stimm- und Verfügungsrechte über die 1.615.469 Aktien werden als geteilt angegeben (keine alleingültigen Rechte gemeldet). Die Einreichung bezieht die Anzahl der ausstehenden Aktien des Emittenten aus dem Quartalsbericht des Emittenten vom 13. Mai 2025.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Anson group disclosed a passive 2.9% stake in SPRO, a non-controlling position that is unlikely to force near-term corporate changes.

The Schedule 13G/A reports 1,615,469 shares (2.9% of 55,910,641 shares). The filing classifies the position as held in the ordinary course of business and not intended to influence control, consistent with passive investor reporting thresholds. Shared voting and dispositive power is indicated across the Anson entities. For investors, this is a transparent ownership disclosure rather than an activist move; it signals interest but not control.

TL;DR: The disclosure documents beneficial ownership and shared authority but shows no group formation or control intent, so governance impact appears limited.

The filing lists multiple affiliated filers and confirms shared voting/dispositive power over 1,615,469 shares (2.9%). Item 10 certification states the stake was not acquired to change control. No members of a group, no greater-than-5% ownership, and no solicitation or group formation are reported. From a governance perspective, this is routine transparency with no immediate governance implications disclosed.

Entità gestite da Anson hanno dichiarato la proprietà beneficiaria di 1.615.469 azioni ordinarie di Spero Therapeutics, pari al 2,9% delle 55.910.641 azioni in circolazione. Le partecipazioni sono riportate in un Schedule 13G/A relativo all’evento del 30/06/2025 e firmato il 14/08/2025 da rappresentanti di Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo e Moez Kassam.

La comunicazione dichiara che le azioni sono detenute dal Fondo e che la posizione è mantenuta nell’ordinario svolgimento dell’attività e non per influenzare il controllo dell’emittente. Il potere di voto e dispositive sulle 1.615.469 azioni è indicato come condiviso (non è riportato alcun potere esclusivo). Il documento cita il conteggio delle azioni in circolazione dell’emittente tratto dal rapporto trimestrale dell’emittente del 13 maggio 2025.

Entidades gestionadas por Anson informaron la propiedad beneficiaria de 1.615.469 acciones ordinarias de Spero Therapeutics, lo que representa el 2,9% de las 55.910.641 acciones en circulación. Las tenencias se revelan en un Schedule 13G/A fechado para el evento 30/06/2025 y firmado el 14/08/2025 por representantes de Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo y Moez Kassam.

La presentación indica que las acciones están en poder del Fondo y que la posición se mantiene en el curso ordinario del negocio y no para influir en el control del emisor. El poder de voto y dispositvo sobre las 1.615.469 acciones figura como compartido (no se informa poder exclusivo). La presentación cita el número de acciones en circulación del emisor según el informe trimestral del emisor del 13 de mayo de 2025.

Anson이 관리하는 법인들은 Spero Therapeutics 보통주 1,615,469주에 대한 실소유자(beneficial ownership)를 신고했으며, 이는 발행주식 총수 55,910,641주의 2.9%에 해당합니다. 보유 내역은 2025-06-30 사건을 위한 Schedule 13G/A에 공개되어 있으며, Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo 및 Moez Kassam의 대리인이 2025-08-14에 서명했습니다.

서류에는 해당 주식이 펀드에 의해 보유되고 있으며 이 지분은 발행인의 지배력에 영향을 주기 위한 것이 아닌 통상적인 사업활동의 일환으로 보유된 것이라고 명시되어 있습니다. 1,615,469주에 대한 의결권 및 처분권은 공동으로 표시되어 있으며(단독 권한은 보고되지 않음) 문서는 발행인의 2025년 5월 13일 분기보고서에 기재된 발행주식 수를 인용하고 있습니다.

Des entités gérées par Anson ont déclaré la propriété bénéficiaire de 1 615 469 actions ordinaires de Spero Therapeutics, représentant 2,9% des 55 910 641 actions en circulation. Les avoirs sont divulgués dans un Schedule 13G/A daté pour l’événement du 30/06/2025 et signé le 14/08/2025 par des représentants d’Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo et Moez Kassam.

Le dépôt indique que les actions sont détenues par le Fonds et que la position est détenue dans le cadre normal des activités et non pour influencer le contrôle de l’émetteur. Le pouvoir de vote et le pouvoir discrétionnaire sur les 1 615 469 actions sont indiqués comme partagés (aucun pouvoir exclusif déclaré). Le dépôt cite le nombre d’actions en circulation de l’émetteur figurant dans le rapport trimestriel de l’émetteur du 13 mai 2025.

Von Anson verwaltete Einheiten meldeten die wirtschaftliche Eigentümerschaft an 1.615.469 Aktien der Stammaktien von Spero Therapeutics, was 2,9% der 55.910.641 ausstehenden Aktien entspricht. Die Bestände sind in einer Schedule 13G/A aufgeführt, datiert auf das Ereignis 30.06.2025 und am 14.08.2025 von Vertretern von Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo und Moez Kassam unterzeichnet.

Die Einreichung gibt an, dass die Aktien vom Fonds gehalten werden und die Position im normalen Geschäftsverlauf gehalten wird und nicht dazu dient, die Kontrolle über den Emittenten zu beeinflussen. Stimm- und Verfügungsrechte über die 1.615.469 Aktien werden als geteilt angegeben (keine alleingültigen Rechte gemeldet). Die Einreichung bezieht die Anzahl der ausstehenden Aktien des Emittenten aus dem Quartalsbericht des Emittenten vom 13. Mai 2025.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Anson Funds Management LP
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Anson Management GP LLC
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Tony Moore
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Anson Advisors Inc.
Signature:/s/ Amin Nathoo
Name/Title:Amin Nathoo, Director
Date:08/14/2025
Signature:/s/ Moez Kassam
Name/Title:Moez Kassam, Director
Date:08/14/2025
Amin Nathoo
Signature:/s/ Amin Nathoo
Name/Title:Amin Nathoo, Director
Date:08/14/2025
Moez Kassam
Signature:/s/ Moez Kassam
Name/Title:Moez Kassam, Director
Date:08/14/2025

FAQ

What stake does Anson report in SPRO?

Anson reports beneficial ownership of 1,615,469 shares, equal to 2.9% of SPRO's 55,910,641 outstanding shares.

Does the filing indicate Anson intends to influence control of Spero (SPRO)?

No. The filing certifies the shares were acquired and are held in the ordinary course of business and not to change or influence control of the issuer.

Who signed the Schedule 13G/A for Anson?

Signatures include Tony Moore for Anson Funds Management LP and Anson Management GP LLC, and Amin Nathoo and Moez Kassam for Anson Advisors Inc.; all dated 08/14/2025.

What type of reporting persons are listed?

Reporting persons include investment adviser and private fund entities and individuals, classified as IA, PN, HC, OO, FI, CO, IN depending on the filer.

What voting and dispositive powers are reported?

The filing reports 0 sole voting/dispositive power and 1,615,469 shared voting and dispositive power for each reporting person.
Spero Therapeuti

NASDAQ:SPRO

SPRO Rankings

SPRO Latest News

SPRO Latest SEC Filings

SPRO Stock Data

108.19M
42.15M
24.61%
22.89%
2.18%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE